Legend Biotech Reports Exceptional Phase 1 Data for In Vivo CAR-T LB2501 with 100% ORR
LEGN has more than doubled off its 52-week low of $16.24.
Summary
Legend Biotech announced compelling Phase 1 clinical data for its investigational in vivo CAR-T therapy, LB2501, showing a 100% objective response rate and 83.3% complete response rate in relapsed/refractory B-cell non-Hodgkin lymphoma patients at the higher dose level, alongside a favorable safety profile.
Key Events · Product Development and Regulatory · LEGN
-
Exceptional Phase 1 Efficacy Data
LB2501 achieved a 100% objective response rate (ORR) and an 83.3% complete response (CR) rate at dose level 2 (DL2) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
-
Favorable Safety Profile
The therapy demonstrated a favorable safety profile with no dose-limiting toxicities (DLTs), serious adverse events (SAEs), immune effector cell-associated neurotoxicity syndrome (ICANS), or deaths reported. Infusion-related reactions and cytokine release syndrome were all Grade 1-2.
-
In Vivo CAR-T Platform Validation
LB2501, an investigational in vivo CAR-T, generated dose-dependent CAR-T expansion directly within patients without requiring lymphodepletion, validating Legend Biotech's next-generation cell therapy platform.
-
EHA 2026 Presentation
The clinical proof-of-concept data was presented in a late-breaking session at the European Hematology Association (EHA) 2026 Congress.
Analysis · LEGN · Life Sciences
This filing provides the full clinical proof-of-concept data for LB2501, an innovative in vivo CAR-T therapy, presented at EHA 2026. The reported 100% objective response rate and 83.3% complete response rate at the higher dose level in heavily pretreated relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) patients are exceptionally strong for a Phase 1 study. The favorable safety profile, with no DLTs, SAEs, or ICANS, and the ability to achieve these results without lymphodepletion, significantly de-risk the program and validate Legend Biotech's next-generation cell therapy platform. This data could position LB2501 as a potential first-in-class, off-the-shelf treatment, expanding access and simplifying CAR-T therapy.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LEGN was trading at $35.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $16.24 to $45.30. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.